Clinical Trial Update: A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy results for AEGR-733 in Homozygous Familial Hypercholesterolemia have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• AEGR-733

Snippet

Sponsor: Aegerion Pharmaceuticals, Inc. | Conditions: Homozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2013-02-22